201 related articles for article (PubMed ID: 8695266)
21. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.
Recchia F; De Filippis S; Torchio P; Rea S; Gulino A; Quaglino D; Frati L
Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202
[TBL] [Abstract][Full Text] [Related]
22. A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer.
Eguchi K; Etou H; Miyachi S; Morinari H; Nakada K; Noda K; Ohkuni Y; Watanabe K; Yamada Y; Ohe Y
Eur J Cancer; 1994; 30A(2):188-94. PubMed ID: 7512356
[TBL] [Abstract][Full Text] [Related]
23. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
[TBL] [Abstract][Full Text] [Related]
24. Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer.
Osborne CK; Sunderland MC; Neidhart JA; Ravdin PM; Abeloff MD
Ann Oncol; 1994 Jan; 5(1):43-7. PubMed ID: 8172792
[TBL] [Abstract][Full Text] [Related]
25. CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: a Hoosier Oncology Group phase II trial.
Sandler A; Blanke C; Monaco F; Carey MA; Ansari R; Fisher B; Spiridonidis CH; Einhorn L; Nichols C
Am J Clin Oncol; 1998 Jun; 21(3):294-7. PubMed ID: 9626802
[TBL] [Abstract][Full Text] [Related]
26. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
Walewski J; Romejko-Jarosińska J; Zwoliński J; Falkowski S; Siedlecki P
Med Oncol; 1996 Dec; 13(4):199-205. PubMed ID: 9152970
[TBL] [Abstract][Full Text] [Related]
27. GM-CSF, carboplatin, doxorubicin: a phase I study.
Poplin EA; Alberts DS; Rinehart JJ; Smith HO; Neidhart JA; Hersh EM
Cancer Chemother Pharmacol; 1994; 33(4):340-6. PubMed ID: 8281628
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy.
Furman WL; Fairclough DL; Huhn RD; Pratt CB; Stute N; Petros WP; Evans WE; Bowman LC; Douglass EC; Santana VM
J Clin Oncol; 1991 Jun; 9(6):1022-8. PubMed ID: 2033415
[TBL] [Abstract][Full Text] [Related]
29. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
[TBL] [Abstract][Full Text] [Related]
30. Use of GM-CSF in children after high-dose chemotherapy.
Furman WL; Fairclough D; Cain AM; Arnold BA; Pratt CB; Meyer WH; Crist WM
Med Pediatr Oncol Suppl; 1992; 2():26-30. PubMed ID: 1306884
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human GM-CSF in small cell lung cancer: a phase I/II study.
Anderson H; Gurney H; Thatcher N; Swindell R; Scarffe JH; Weiner J
Recent Results Cancer Res; 1991; 121():155-61. PubMed ID: 1650015
[TBL] [Abstract][Full Text] [Related]
32. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.
Sternberg CN; de Mulder PH; van Oosterom AT; Fossa SD; Giannarelli D; Soedirman JR
Ann Oncol; 1993 May; 4(5):403-7. PubMed ID: 8353075
[TBL] [Abstract][Full Text] [Related]
33. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
34. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
36. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
Weiss GR; Shaffer DW; DeMoor C; Rinaldi DA; Rodriguez GI; Eckardt JR; Stephens C; Von Hoff DD
Anticancer Drugs; 1996 Jun; 7(4):402-9. PubMed ID: 8826608
[TBL] [Abstract][Full Text] [Related]
38. [Colony stimulating factors in polychemotherapy of testicular tumors. A comparison between G-CSF and GM-CSF].
Will R; Hofmockel G; Langer W; Frohmüller H
Urologe A; 1999 May; 38(3):258-63. PubMed ID: 10407985
[TBL] [Abstract][Full Text] [Related]
39. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
Partyka S; Dumas P; Ajani J
Cancer; 1999 Jun; 85(11):2336-9. PubMed ID: 10357402
[TBL] [Abstract][Full Text] [Related]
40. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
